N-Acetyl Cysteine Therapy Does Not Prevent Renal Failure in High-Risk Patients Undergoing Open-Heart Surgery

Authors

  • Abeer M Rababa’h Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid
  • Salil V. Deo Department of Cardiovascular Surgery, Case Western Reserve University, Cleveland, Ohio
  • Salah E. Altarabsheh Department of Cardiac Surgery, Queen Alia Heart Institute, Amman
  • Jessica De Caro Cleveland Health Sciences Library, Case Western Reserve University, Cleveland, Ohio
  • Nafez Abu Tarboush Department of Physiology and Biochemistry, Faculty of Medicine, The University of Jordan, Amman
  • Karem H. Alzoubi Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid
  • Mera Ababneh Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid
  • Bradley K. McConnell Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Texas Medical Center, Houston, Texas
  • Alan H. Markowitz Department of Cardiovascular Surgery, Case Western Reserve University, Cleveland, Ohio
  • Soon J. Park Department of Cardiovascular Surgery, Case Western Reserve University, Cleveland, Ohio

DOI:

https://doi.org/10.1532/hsf.1424

Abstract

Background: Renal dysfunction is a common complication after cardiovascular surgery. Controversial issues have been discussed regarding the role of N-acetyl cysteine in the prevention of postoperative renal dysfunction. The purpose of this meta-analysis is to assess whether N-acetyl cysteine offers any protection against the development of acute renal dysfunction after cardiac surgery.
Methods: Multiple databases were searched for randomized trials comparing the role of N-acetyl cysteine and placebo in human patients undergoing cardiac surgery. End-points studied were: the incidence of acute renal failure, hemodialysis, early mortality, duration of hospital stay, and maximal change in creatinine values. Dichotomous variables were compared using the risk difference (RD) calculated with inverse weighting; continuous data was pooled as (standardized) mean difference. Results are presented with 95% confidence interval (P < .05 is significant); results are presented within 95% confidence interval.
Results: Thirteen randomized trials (713 and 707 patients in the N-acetyl cysteine and control groups, respectively) were included in the present analysis; nine dealing with patients at high-risk for acute renal failure. The incidence of postoperative acute renal dysfunction was 23% and 36% in the N-acetyl cysteine and control cohorts, respectively. N-acetyl cysteine therapy did not reduce acute renal dysfunction in the high-risk cohort [RD -0.03 (-0.09 to 0.02); P = .22; I2 = 24%]. Maximal change in creatinine levels after surgery was also comparable [standardized mean difference 0.07 (-0.23, 0.09); P = .39]. Early mortality was 2.9% and 3.7% in the N-acetyl cysteine and control cohorts respectively; [RD 0 (-0.03 to 0.02); P = .63; I2 = 20%]. Hospital stay (mean length of stay 10.4 and 10.1 days in the N-acetyl cysteine and control cohorts, respectively) was also similar in both cohorts [WMD 0.17 (-0.02 to 0.37) days; P = .81].
Conclusion: Prophylactic N-acetyl cysteine therapy does not reduce the incidence of renal dysfunction in high-risk patients undergoing cardiac surgery.

References

Adabag AS, Ishani A, Koneswaran S, et al. 2008. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J 155:1143-9.

Adabag AS, Ishani A, Bloomfield HE, Ngo AK, Wilt TJ. 2009. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 30:1910-17.

Barr LF, Kolodner K. 2008. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit Care Med. 36:1427-35.

Burns KE, Chu MW, Novick RJ, et al. 2005. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial. JAMA 294:342-50.

El-Hamamsy I, Stevens LM, Carrier M, et al. 2007. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 133:7-12.

Fischer UM, Tossios P, Mehlhorn U. 2005. Renal protection by radical scavenging in cardiac surgery patients. Curr Med Res Opinion 21:1161-4.

Haase M, Haase-Fielitz A, Bagshaw SM, et al. 2007. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 35:1324-31.

Ho KM, Morgan DJ. 2009. Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery. Am J Kid Dis 53:33-40.

Liberati A, Altman DG, Tetzlaff J, et al. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34.

Mehta RL, Kellum JA, Shah SV, et al. 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31.

Orhan G, Yapici N, Yuksel M, et al. 2006. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart and Vessels 21:42-7.

Prasad A, Banakal S, Muralidhar K. 2010. N-acetylcysteine does not prevent renal dysfunction after off-pump coronary artery bypass surgery. European journal of anaesthesiology. 27:973-7.

Ristikankare A, Kuitunen T, Kuitunen A, et al. 2006. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Brit J Anaesth 97:611-16.

Santana-Santos E, Gowdak LH, Gaiotto FA, et al. 2014. High dose of N-acetylcystein prevents acute kidney injury in chronic kidney disease patients undergoing myocardial revascularization. Ann Thorac Surg 97:1617-23.

Sisillo E, Ceriani R, Bortone F, et al. 2008. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 36:81-6.

Song JW, Shim JK, Soh S, Jang J, Kwak YL. 2015. Double-blinded, randomised controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass. Nephrology 20:96-102.

Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. 2000. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. New Engl J Med 343:180-4.

van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review G. 2003. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine 28:1290-9.

Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT. 2007. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. J Can D’anesth 54:872-81.

Zhu J, Yin R, Shao H, Dong G, Luo L, Jing H. 2007. N-acetylcysteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg 133:696-703

Published

2016-02-22

How to Cite

Rababa’h, A. M., Deo, S. V., Altarabsheh, S. E., De Caro, J., Tarboush, N. A., Alzoubi, K. H., Ababneh, M., McConnell, B. K., Markowitz, A. H., & Park, S. J. (2016). N-Acetyl Cysteine Therapy Does Not Prevent Renal Failure in High-Risk Patients Undergoing Open-Heart Surgery. The Heart Surgery Forum, 19(1), E016-E022. https://doi.org/10.1532/hsf.1424

Issue

Vol. 19 No. 1 (2016)

Section

Article
Author Disclosure & Copyright Transfer Agreement